QuidelOrtho Corp (QDEL) stock
QDELNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends January 1
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/3063% below fair value
$9.57−0.30 (-3.04%)
Close on Nov 18, 2026Market cap $656.27MP/E –Yield –
QuidelOrtho operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
QuidelOrtho's operating cash flow for the twelve months ending Sep 27, 2026 was $7.90M, down 78.6% year over year. For fiscal 2025 it was $105.20M, up 26.7% from the year before. The highest annual figure on record is $885.30M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 28, 2025 | $105.20M | +26.7% |
| FY2024 | Dec 29, 2024 | $83.00M | -70.4% |
| FY2023 | Dec 31, 2023 | $280.20M | -68.3% |
| FY2022 | Jan 1, 2023 | $885.30M | +9.9% |
| FY2021 | Jan 2, 2022 | $805.90M | +28.0% |
| FY2020 | Jan 3, 2021 | $629.70M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 27, 2026 | $19.60M | – |
| Q2 FY2026 | Jun 28, 2026 | -$110.60M | – |
| Q1 FY2026 | Mar 29, 2026 | -$33.00M | -150.3% |
| Q4 FY2025 | Dec 28, 2025 | $131.90M | +107.1% |
| Q3 FY2025 | Sep 28, 2025 | -$45.50M | -138.6% |
| Q2 FY2025 | Jun 29, 2025 | -$46.80M | – |
| Q1 FY2025 | Mar 30, 2025 | $65.60M | – |
| Q4 FY2024 | Dec 29, 2024 | $63.70M | -20.8% |
| Q3 FY2024 | Sep 29, 2024 | $117.90M | +184.1% |
| Q2 FY2024 | Jun 30, 2024 | -$97.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$700.00K | -100.4% |
| Q4 FY2023 | Dec 31, 2023 | $80.40M | -52.5% |
| Q3 FY2023 | Oct 1, 2023 | $41.50M | – |
| Q2 FY2023 | Jul 2, 2023 | -$30.60M | -113.6% |
| Q1 FY2023 | Apr 2, 2023 | $188.90M | -62.3% |
| Q4 FY2022 | Jan 1, 2023 | $169.40M | -47.3% |
| Q3 FY2022 | Oct 2, 2022 | -$9.70M | -112.6% |
| Q2 FY2022 | Jul 3, 2022 | $224.70M | – |
| Q1 FY2022 | Apr 3, 2022 | $500.90M | – |
| Q4 FY2021 | Jan 2, 2022 | $321.40M | – |
| Q3 FY2021 | Oct 3, 2021 | $77.00M | – |
See a number that looks wrong?